erlotinib hydrochloride has been researched along with Brain Neoplasms in 188 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 43 (22.87) | 29.6817 |
| 2010's | 123 (65.43) | 24.3611 |
| 2020's | 22 (11.70) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, S; Elmquist, WF; Manchanda, P; Ohlfest, JR; Vogelbaum, MA | 1 |
| Cui, H; Geng, S; Hou, J; Hu, X; Liang, H; Peng, W; Shi, S; Sun, X; Wang, F; Zhang, J; Zhong, D; Zhong, J | 1 |
| Cole, BL; Leary, SES; Lockwood, CM; Starr, K | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Lee, SH; Park, S; Sun, JM | 1 |
| Li, R; Li, S; Li, W; Zhang, F | 1 |
| Chang, HC; Chang, YP; Chen, YM; Chuang, HY; Fang, WF; Huang, KT; Lai, CH; Lin, MC; Tseng, CC; Wang, CC | 1 |
| Chiu, TH; Chung, FT; Fang, YF; Guo, YK; Hsu, PC; Huang, AC; Huang, CH; Ju, JS; Ko, HW; Kuo, CS; Tung, PH; Wang, CC; Yang, CT | 1 |
| Chang, CC; Lin, CC; Lin, CY; Su, PL; Su, WC; Tseng, YL; Yen, YT | 1 |
| Chang, LC; Chang, LY; Chen, KY; Lim, CK; Shih, JY; Yu, CJ | 1 |
| Chen, CY; Chen, YF; Chen, YH; Shih, JY; Yu, CJ | 1 |
| An, Z; Fan, QW; Haas-Kogan, DA; Lu, M; Luo, X; Phillips, JJ; Shokat, KM; Weiss, WA; Wong, RA | 1 |
| Deng, Q; He, D; Wang, F; Xie, Z; Yang, H | 1 |
| Catapano, J; Czyż, J; Król, K; Pudełek, M; Ryszawy, D; Wróbel, T | 1 |
| Gota, V; Gurjar, M; Joshi, A; Kannan, S; Nookala, M; Noronha, V; Patil, A; Patil, D; Patil, V; Prabhash, K; Shriyan, B | 1 |
| Cenci, T; D'Alessandris, QG; DI Bonaventura, R; Larocca, LM; Lauretti, L; Martini, M; Montano, N; Olivi, A; Pallini, R; Stumpo, V | 1 |
| Chen, M; Chen, W; Han, G; Jiang, Y; Mao, S; Shi, N; Yu, W; Zhang, X | 1 |
| Chiu, CH; Enatsu, S; Frimodt-Moller, B; Garon, EB; Homma, G; Imamura, F; Nakagawa, K; Nishio, M; Park, K; Reck, M; Seto, T; Shih, JY; Visseren-Grul, C; Yoh, K; Zimmermann, A | 1 |
| Carbone, DP; Chen, L; Li, J; Li, R; Liao, Z; Ren, B; Sun, J; Xia, X; Yang, Z; Yisikandaer, A; Zhang, J; Zhang, Y; Zhao, R | 1 |
| Cao, D; Hu, B; Hwang, I; Jang, JY; Li, JY; Oh, H; Paik, J; Wang, Q; Wu, L; Yao, J; Yao, Y; Ying, H; Zheng, H | 1 |
| Lou, E; Sperduto, PW | 1 |
| Alonso Garcia, M; Fabre, E; Frimodt-Moller, B; Garon, EB; Moro-Sibilot, D; Nadal, E; Nakagawa, K; Novello, S; Ponce Aix, S; Reck, M; Visseren-Grul, CM; Zimmermann, AH | 1 |
| Dong, Y; Li, D; Li, Q; Miao, Q | 1 |
| Atagi, S; Daga, H; Izumi, M; Kaneda, H; Kawaguchi, T; Matsumoto, Y; Mitsuoka, S; Nakahama, K; Nakatani, Y; Ogawa, K; Okada, A; Okishio, K; Sawa, K; Tani, Y | 1 |
| Batchelder, E; Drabick, JJ; Lehrer, EJ; Machtay, M; Sharma, N; Tchelebi, LT; Trifiletti, DM; Wang, M; Zaorsky, NG | 1 |
| Chen, GY; Cheng, Y; Cui, JW; Huang, C; Li, XL; Liu, YP; Lu, S; Ma, ZY; Shu, YQ; Song, Y; Tu, HY; Wang, Z; Wu, YL; Xu, CR; Yang, JJ; Yang, N; Yu, SY; Zhong, WZ; Zhou, JY; Zhou, Q | 1 |
| He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX | 1 |
| Broniscer, A; Hua, CH; Hwang, SN; Knapp, BJ; Lucas, JT; Merchant, TE; Patay, Z; Uh, J | 1 |
| Foster, A; Patel, SH; Riely, GJ; Rimner, A; Woo, KM; Wu, AJ; Yu, HA; Zhang, Z | 1 |
| Hanselman, JS; Harley, BAC; Pedron, S; Sarkaria, JN; Schroeder, MA | 1 |
| Broniscer, A; Cooper, DA; Hwang, S; Li, X; Li, Y; Lucas, JT; Merchant, TE; Orr, B; Tinkle, C | 1 |
| Ahn, L; Arbour, KC; Beal, K; Daras, M; Hayes, SA; Kris, MG; Ni, A; Pao, W; Riely, GJ; Rodriguez, CR; Young, RJ; Yu, HA | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Li, B; Li, Y; Liu, J; Liu, S; Tang, Y; Yuan, D; Yuan, X | 1 |
| Chen, KY; Chen, TT; Chuang, HC; Feng, PH; Han, CL; Huang, YC; Kuo, CH; Lee, CN; Lee, KY; Lee, WH; Lin, CF; Luo, CS; Wu, SM; Yeh, CT | 1 |
| Guan, S; Ji, G; Yao, X; Zhang, C | 1 |
| Baxa, U; Majumder, P; Schneider, JP; Walsh, STR | 1 |
| Lakkadwala, S; Singh, J | 1 |
| Cenci, T; D'Alessandris, QG; Fernandez, E; Larocca, LM; Lauretti, L; Martini, M; Montano, N; Olivi, A; Pallini, R; Pignotti, F; Stumpo, V | 1 |
| Choi, CM; Choi, YJ; Cook, S; Jin, YS; Kim, DH; Kim, JK; Lee, EY; Lee, JC; Rho, JK; Sung, KJ; Sung, YH; Yoo, SA; Yun, M | 1 |
| Cao, L; Huang, J; Jiang, Y; Li, N; Xu, B; Zhang, J; Zhao, M | 1 |
| Abdulla, DSY; Brandes, V; Büttner, R; Drzezga, A; Fischer, R; Galldiks, N; Grau, S; Kobe, C; Kunze, S; Merkelbach-Bruse, S; Michels, S; Nogova, L; Persigehl, T; Riedel, R; Ruge, M; Scheffler, M; Wolf, J | 1 |
| Fujii, K; Ichiyasu, H; Ikeda, T; Imamura, K; Kashiwabara, K; Komatu, T; Maruyama, H; Saeki, S; Sakagami, T; Saruwatari, K; Shingu, N; Tomita, Y; Ushijima, S | 1 |
| Erikson, AK; Paripati, HR; Sheedy, JT; Shoudis, SN; Sio, TT; Yu, NY | 1 |
| Endo, M; Gon, Y; Harada, H; Kawamura, T; Kenmotsu, H; Kobayashi, H; Mamesaya, N; Mitsuya, K; Miyawaki, E; Mori, K; Murakami, H; Naito, T; Nakashima, K; Nakasu, Y; Omori, S; Ono, A; Takahashi, T; Wakuda, K | 1 |
| Borghaei, H; Camidge, R; Deal, A; Kavanagh, B; Kirpalani, P; Lee, C; Morris, D; Pecot, CV; Pennell, N; Stevenson, J; Stinchcombe, T; Villaruz, L; Weiss, J; West, J; Zagar, T | 1 |
| Brell, M; Fernández de Mattos, S; Ramis, G; Serra-Sitjar, M; Villalonga, P; Villalonga-Planells, R | 1 |
| Dos Santos Rodrigues, B; Lakkadwala, S; Singh, J; Sun, C | 1 |
| Chen, JE; Harley, BAC; Laken, SE; Pedron, S; Sarkaria, JN; Wolter, GL | 1 |
| Hayashi, N; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Masuda, N; Nagashima, Y | 1 |
| Akhavan, D; Babic, I; Bensinger, SJ; Cavenee, WK; Cloughesy, TF; Dang, J; Flagg, M; James, CD; Kornblum, HI; Mischel, PS; Nael, A; Nathanson, D; Nourian, AA; Pourzia, AL; Sasayama, T; Tamanoi, F; Tanaka, K; Villa, GR; Vinters, HV; Williams, KJ; Yang, H; Yong, WH | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Kathagen, A; Kolbe, K; Lamszus, K; Liffers, K; Merlo, A; Riethdorf, S; Schulte, A; Westphal, M; Zapf, S | 1 |
| Fishbein, M; Marchevsky, A; Reckamp, KL; Saldivar, JS; Scher, KS | 1 |
| Agar, JN; Agar, NY; Alberta, J; Davis, E; Easterling, ML; Ebling, MC; Ide, JL; Kellersberger, KA; Kesari, S; Liu, X; Marchionni, MA; Norton, I; Santagata, S; Sauvageot, CM; Stiles, CD; Stuart, DD; Wang, LY | 1 |
| Pang, Q; Wang, J; Wang, P; Yuan, Z; Zhao, L; Zhuang, H | 1 |
| Song, Z; Zhang, Y | 1 |
| Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Drappatz, J; Gilbert, MR; Groves, MD; Kuhn, JG; Lamborn, KR; Lieberman, FS; Ligon, AH; Ligon, KL; Mehta, MP; Norden, AD; Prados, MD; Robins, HI; Santagata, S; Wen, PY; Wright, JJ; Yung, WK | 1 |
| Butowski, NA; Chang, SM; Clarke, JL; Costello, JF; DeSilva, AA; Molinaro, AM; Perry, A; Phillips, JJ; Prados, MD; Rabbitt, JE | 1 |
| Beal, K; Chan, TA; Gerber, NK; Riely, GJ; Rimner, A; Shi, W; Wu, AJ; Yamada, Y; Yu, HA; Zhang, Z | 1 |
| Dziadziuszko, R; Peters, S; Zimmermann, S | 1 |
| Addeo, R; Caraglia, M; Parlato, C; Zappavigna, S | 1 |
| Meng, X; Sun, X; Yu, J; Zhang, J | 1 |
| Bates, A; Counsell, N; Faivre-Finn, C; Hackshaw, A; Lee, SM; Lewanski, CR; Ngai, Y; Ottensmeier, C; Patel, N; Wadsworth, C | 1 |
| Arai, M; Hayashihara, K; Iwasawa, T; Kato, T; Ogura, T; Ohashi, K; Okudela, K; Saito, T; Satoh, H; Sekine, A; Tamura, K | 1 |
| Brown, D; Butowski, N; Cheng, SY; Giles, FJ; James, CD; Mazar, AP; Nicolaides, T; Ozawa, T; Parsa, AT; Raizer, JJ; Sarkaria, JN; Shen, W; Stegh, AH; Yao, TW; Yoshida, Y | 1 |
| Chang, SM; Clarke, J; Jalilian, L; Lupo, JM; Molinaro, AM; Nelson, SJ; Prados, M; Wen, Q | 1 |
| Cavenee, WK; Chen, CC; Furnari, FB; Gomez, GG; Gonias, SL; Hu, J; Mischel, PS; Pizzo, D; Taylor, T; Thorne, AH; VandenBerg, SR; Villa, GR; Wykosky, J | 1 |
| Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H | 1 |
| Allen, PK; Blumenschein, GR; Hong, WK; Komaki, R; Lee, JJ; Liu, DD; Tang, X; Wei, X; Welsh, JW; Wistuba, II | 1 |
| Chen, L; Chen, X; Luo, S; Xie, X | 1 |
| Bi, Z; Jiang, Y; Li, D; Liu, Y | 1 |
| Jatoi, A; Olivier, KR; Spiceland, CM | 1 |
| Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M | 1 |
| Aldape, K; Chamberlain, M; Conrad, C; De Groot, J; Giglio, P; Gilbert, MR; Grimm, S; Groves, M; Hu, J; Liu, D; Loghin, M; Merrell, R; Paleologos, N; Phuphanich, S; Puduvalli, VK; Rademaker, A; Raizer, JJ; Rudnick, J; Tremont-Lukats, IW; Vaillant, B; Vick, N; Yuan, Y; Yung, WK | 1 |
| Iwasa, T; Kaneda, H; Nakagawa, K; Nonagase, Y; Okamoto, K; Shimizu, T; Takeda, M; Tanaka, K; Tsurutani, J; Yoshida, T | 1 |
| Chen, G; De Grève, J; De Wever, O; Geers, C; Giron, P; Noeparast, A; Renard, M; Teugels, E; Umelo, I; Vansteenkiste, J | 1 |
| Kulshreshtha, D; Nanda, SS; Prakash, C; Rastogi, M | 1 |
| Heath, JR; Johnson, D; Su, Y; Wei, W; Xue, M | 1 |
| Brower, JV; Robins, HI | 1 |
| Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH | 1 |
| Heath, JR; Johnson, H; Kravchenko-Balasha, N; Levine, RD; White, FM | 1 |
| Bell, D; Garber, ST; Janku, F; Khoury, L; McCutcheon, IE; Schomer, DF | 1 |
| Ali, SM; Blumenthal, DT; Bokstein, F; Dvir, A; Limon, D; Lior, T; Lokiec, A; Lossos, A; Ram, Z; Ross, JS; Soussan-Gutman, L; Tzuk-Shina, T; Yair, R; Yust-Katz, S | 1 |
| Cruz, P; de Castro, J; de Lujan, L | 1 |
| Chen, Z; Jiang, B; Su, J; Wu, YL; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhou, Q | 1 |
| Hosomi, Y; Kashima, J; Miwa, M; Okuma, Y | 1 |
| Homma, M; Kaburagi, T; Kurosawa, A; Ohgami, M | 1 |
| Ahluwalia, MS; Amini, A; Attia, A; Balasubramanian, SK; Beal, K; Boreta, LC; Braunstein, SE; Camidge, DR; Chiang, VL; Contessa, JN; Gerber, NK; Gettinger, SN; Kavanagh, BD; Lester-Coll, NH; Lockney, NA; Magnuson, WJ; Patil, T; Rana, NG; Wu, AJ; Yang, TJ; Yu, JB | 1 |
| Ariyasu, R; Horiike, A; Kawashima, Y; Kitazono, S; Koyama, J; Nishikawa, S; Nishio, M; Oguri, T; Ohyanagi, F; Saiki, M; Sonoda, T; Takano, N; Yanagitani, N | 1 |
| Baggstrom, MQ; How, J; Laczniak, AN; Mann, J | 1 |
| Altavilla, G; Arrigo, C; Galletti, G; Marabello, G; Picone, G; Pitini, VV; Santarpia, MC; Tomasello, C | 1 |
| Aldape, K; Colman, H; Conrad, C; de Groot, JF; Gilbert, MR; Groves, MD; Hanna, TA; Hess, KR; Ictech, S; Levin, V; Puduvalli, VK; Yung, WK | 1 |
| Braiteh, F; Johnson, FM; Kurzrock, R | 1 |
| Adamson, PC; Blaney, SM; Dancey, JE; Gilbertson, RJ; Hamilton, M; Ingle, AM; Jakacki, RI; Krailo, MD; Tersak, J; Voss, SD | 1 |
| Ayers-Ringler, J; Berger, MS; Butowski, N; Carliner, H; Chang, SM; DeBoer, R; Fedoroff, A; Haas-Kogan, DA; James, CD; Kabuubi, P; Lamborn, KR; McDermott, MW; Page, M; Parsa, AT; Parvataneni, R; Prados, MD; Rabbitt, J; Sneed, PK; Stokoe, D; Vandenberg, S | 1 |
| Baker, SJ; Broniscer, A; Ellison, DW; Endersby, R; Gajjar, A; Kocak, M; Laningham, FH; Merchant, TE; Morris, EB; Schaiquevich, P; Stewart, CF | 1 |
| Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH | 1 |
| Armand, JP; Baurain, JF; Brandes, AA; Campone, M; Carpentier, AF; Clement, PM; Frenay, M; Gorlia, T; Kletzl, H; Klughammer, B; Kouwenhoven, MC; Kros, JM; Lacombe, D; Rampling, R; Taphoorn, MJ; Tosoni, A; van den Bent, MJ | 1 |
| Gajjar, A; Wright, KD | 1 |
| Lagerwaard, FJ; Lind, JS; Senan, S; Smit, EF | 1 |
| Benedetti, G; Colucci, G; Crinò, L; Galetta, D; Latini, L | 1 |
| Broniscer, A; Christiansen, SR; Panetta, JC; Stewart, CF | 1 |
| Cornet, K; Foss, CA; Goodwin, CR; Kim, J; Lal, B; Laterra, J; Muzamil, S; Pomper, MG; Sang, Y | 1 |
| D'Elia, A; Formichella, AI; Frati, A; Salvati, M | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Akerley, W; Compton, P; Huang, JE; Kolb, MM; Langer, CJ; Socinski, MA; Wang, L | 1 |
| Nagai, A; Shiroma, T; Yamaguchi, M | 1 |
| Bonnichon, A; Le Floch, H; Mairovitz, A; Margery, J; Rivière, F; Staub, E; Vaylet, F | 1 |
| Agarwal, N; Ahluwalia, MS; Barnett, GH; Brewer, CJ; Elson, P; Peereboom, DM; Shepard, DR; Stevens, GH; Suh, JH; Toms, SA; Vogelbaum, MA; Weil, RJ | 1 |
| Hammersley, JR; Kanjwal, S; Taj, A | 1 |
| Besse, B; Soria, JC; Vignot, S | 1 |
| Abrey, LE; Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Abrey, LE; Aldape, KA; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Kuhn, JG; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Boockvar, JA; Edgar, MA; Karampelas, I; Luther, N; Souliopoulos, EP; Souweidane, MM | 1 |
| Butler, JS; Donahue, BR; Huang, Y; Olmez, I; Rubin, P; Xu, Y | 1 |
| Dalhaug, A; Nieder, C | 1 |
| Gao, HJ; Guo, WF; Li, JJ; Li, XY; Liu, B; Liu, XQ; Qu, LL; Tang, CH; Wang, WW; Wang, WX | 1 |
| Calles, A; Custodio, A; Pérez-Segura, P | 1 |
| Catot, S; Colomer, R; de Castro, J; Guillem, V; Gúrpide, A; Isla, D; Lianes, P; Massutí, B; Mayo, C; Paz-Ares, L; Polo, E; Porta, R; Pradas, A; Puig, T; Queralt, C; Reguart, N; Rosell, R; Salinas, P; Sánchez-Torres, JM; Tarón, M | 1 |
| Cloughesy, TF; Gilbert, MR; Klencke, B; Nghiemphu, P; Prados, MD; Reardon, DA; Vredenburgh, JJ; Yung, WK | 1 |
| Desjardins, A; Friedman, HS; Gururangan, S; Hamilton, M; Herndon, JE; Marcello, J; Mathe, A; McLendon, RE; Norfleet, JA; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Becker, A; Postmus, PE; Smit, EF; van Wijk, A | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
| Halatsch, ME; Karpel-Massler, G; Wirtz, CR | 1 |
| Chatelut, E; Civade, E; Delord, JP; Geoerger, B; Hennebelle, I; Le Deley, MC; Thomas, F; Vassal, G; White-Koning, M | 1 |
| Halatsch, ME; Karpel-Massler, G; Kast, RE; Westhoff, MA; Wirtz, CR | 1 |
| Chida, K; Inui, N; Matsuura, S; Nakamura, Y; Ozawa, Y; Shirai, T; Suda, T; Suganuma, H; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Kagohashi, K; Kawaguchi, M; Kurishima, K; Nakayama, H; Ohara, G; Satoh, H | 1 |
| Kim, C; Lee, KB; Shah, BP; Subramaniam, P | 1 |
| Erasmus, JJ; Stewart, DJ | 1 |
| Keiding, S; Meldgaard, P; Memon, A; Nexo, E; Sorensen, BS; Sorensen, L; Weber, B; Winterdahl, M | 1 |
| Lanuti, M; Mino-Kenudson, M; Sequist, LV; Sharma, A | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Chao, YS; Cherniack, AD; Chiang, D; Cho, J; Dutt, A; Johnson, W; Kesari, S; Kwon, J; Meyerson, M; Onofrio, RC; Pastorino, S; Vandenberg, S; Verhaak, R; Watanabe, H; Xu, X; Yuza, Y; Zeng, Q | 1 |
| Lee, SH | 1 |
| Amberger-Murphy, V; Clarke, C; Clynes, M; Doolan, P; Farrell, M; Howley, R; Kinsella, P; Madden, SF | 1 |
| Bai, H; Han, B | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Herndon, JE; McLendon, RE; McSherry, F; Peters, KB; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Threatt, S; Vredenburgh, JJ; Zhang, S | 1 |
| Constantini, S; Kane, R; MacDonald, TJ; McCowage, G; Packer, RJ; Rood, B; Yalon, M | 1 |
| Baldotto, CS; da Silveira, JS; de Lima Araújo, LH; Ferreira, CG; Zukin, M | 1 |
| Lemmon, MA; Park, JH | 1 |
| Barkovich, KJ; Blair, JA; Fan, QW; Garske, AL; Hariono, S; Nicolaides, T; Shokat, KM; Weiss, WA; Zhang, J | 1 |
| Brennan, CW; Campos, C; Chang, SM; Chheda, MG; Cloughesy, TF; Dang, J; DeAngelis, LM; Drappatz, J; Fine, HA; Gilbert, MR; Grommes, C; Heguy, A; Horvath, S; Iwanami, A; Kubek, S; Kuga, D; Kuhn, JG; Lamborn, KR; Lassman, AB; Liau, LM; Lieberman, F; Mehta, MP; Mellinghoff, IK; Mischel, PS; Nghiemphu, PL; Oldrini, B; Pedraza, A; Prados, MD; Reardon, DA; Robins, HI; Rohle, D; Tao, H; Vivanco, I; Wen, PY; Wu, N; Yannuzzi, N; Yong, WH; Yung, WK; Zhu, S | 1 |
| Guo, Z; Li, J | 1 |
| Kim, HT; Kim, KP; Kim, SW; Lee, DH; Lee, JS; Park, SJ; Suh, C | 1 |
| Bachoo, RM; Cavenee, WK; Dang, J; DePinho, RA; Fenton, TR; Furnari, FB; Inda, MM; Iwanami, A; James, CD; Kuga, D; Marie, SK; Mischel, PS; Nathanson, D; Oba-Shinjo, SM; Ponte de Albuquerque, C; Tanaka, K; Uno, M; Vandenberg, SR; Wykosky, J; Yang, H; Zhou, H | 1 |
| Cloughesy, T; Green, RM; Lai, A; Nghiemphu, PL; Reardon, DA | 1 |
| Boockvar, JA; Christos, P; Kaplan, R; Kesavabhotla, K; Lavi, E; Mubita, L; Pannullo, SC; Scheff, R; Schlaff, CD; Shin, B; Tsiouris, AJ | 1 |
| Antoine, M; Blons, H; Buisine, MP; Cadranel, J; Chetaille, B; Chouaid, C; Coudert, B; Daniel, C; Danton, G; De Fraipont, F; Faller, M; Foucher, P; Lacroix, L; Longchampt, E; Mauguen, A; Michiels, S; Morin, F; Pignon, JP; Poulot, V; Quoix, E; Solassol, J; Urban, T; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Bianchi, L; Lisi, P; Minotti, V; Stingeni, L | 1 |
| Airiau, K; Avril, T; Belaud-Rotureau, MA; Belloc, F; Dugay, F; Eimer, S; Quillien, V | 1 |
| Chen, GY; Cheng, Y; Huang, C; Huang, YS; Liu, Y; Lu, S; Ren, S; Wu, YL; Yan, HH; Yang, JJ; Zhou, C | 1 |
| Bianchi, F; Cenci, T; D'Alessandris, QG; Fernandez, E; Larocca, LM; Lauretti, L; Maira, G; Martini, M; Montano, N; Pallini, R | 1 |
| Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Akerley, W; Boucher, K; Bylund, J; Egbert, L; Harker, G; Reddy, C; Rich, N; Van Duren, T | 1 |
| Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
| Allen, PK; Amini, A; Brown, P; Chang, JY; Chen, SS; Garland, LL; Heymach, JV; Holt, J; Kim, ES; Komaki, R; Liao, Z; McGovern, SL; Munsell, MF; Stea, B; Sulman, E; Unger, W; Wefel, JS; Welsh, JW | 1 |
| Buyyounouski, MK; Demas, W; Khuntia, D; Komaki, R; Mehta, MP; Nedzi, LA; Perry, G; Robins, HI; Schell, MC; Shah, SA; Souhami, L; Sperduto, PW; Suh, JH; Wang, M; Werner-Wasik, M | 1 |
| Raizer, JJ | 1 |
| Kurisu, K; Okamura, T | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Boshoff, C; Falzon, M; Lai, CS; Lee, SM | 1 |
| Burton, E; Butowski, N; Chang, S; Fedoroff, A; Kapadia, A; Kelley, SK; Lamborn, KR; Malec, M; Page, MS; Prados, MD; Rabbitt, J; Xie, D | 1 |
| Behnke-Mursch, J; Halatsch, ME; Schmidt, U; Unterberg, A; Wirtz, CR | 1 |
| Berger, MS; Keles, GE | 1 |
| Ballman, KV; Brown, PD; Buckner, JC; Fiveash, JB; Geoffroy, FJ; Giannini, C; Jaeckle, KA; Krishnan, S; Nabors, LB; Uhm, JH | 1 |
| Mitra, SS; Simcock, R | 1 |
| Gaya, A; Khorshid, M; Plowman, PN; Walther, JC | 1 |
| Hughes, S; Meehan, L; Moore, S; Norton, A; O'Brien, M; Papadopoulos, P; Popat, S; Priest, K; Wilkins, A | 1 |
| Bai, F; Broniscer, A; Fraga, C; Gajjar, A; Krasin, MJ; O'Shaughnessy, M; Panetta, JC; Stewart, CF | 1 |
| Carlson, BL; Dinca, EB; Galanis, E; Giannini, C; Grogan, PT; James, CD; Kitange, GJ; Sarkaria, JN; Schroeder, MA; Wu, W; Yang, L | 1 |
| Gabizon, A; Gipps, M; Grenader, T; Shavit, L | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Huang, MY; Huang, YJ; Liu, SF; Wang, CJ | 1 |
| Bradner, JE; Brennan, C; Chin, L; DePinho, RA; Kimmelman, AC; Ligon, KL; Nabioullin, R; Ponugoti, AH; Stegh, AH; Stommel, JM; Wiedemeyer, R; Ying, H | 1 |
| Pan, M; Santamaria, M; Wollman, DB | 1 |
| Cadranel, J; Gounant, V; Khalil, A; Lavole, A; Milleron, B; Poulot, V; Wislez, M | 1 |
| Fekrazad, MH; Jones, DV; Ravindranathan, M | 1 |
| Costa, DB; Kobayashi, S | 1 |
| Duell, T; Poellinger, B; von Pawel, J; Wagner, H | 1 |
| Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G | 1 |
| Liau, LM; Salgaller, ML | 1 |
25 review(s) available for erlotinib hydrochloride and Brain Neoplasms
| Article | Year |
|---|---|
Bevacizumab plus erlotinib versus erlotinib alone for advanced EGFR-mutant non-small cell lung cancer: a meta-analysis of randomized clinical trials.
Topics: Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2023 |
Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta-analysis of real-world survival outcomes of East Asian patients with advanced non-small cell lung cancer treated with first-line EGFR-TKIs.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; East Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Network Meta-Analysis; Protein Kinase Inhibitors; Treatment Outcome; Tyrosine Kinase Inhibitors | 2023 |
Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review.
Topics: Biopsy; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Response Evaluation Criteria in Solid Tumors; Salvage Therapy | 2021 |
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies.
Topics: Bevacizumab; Brain Neoplasms; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Erlotinib Hydrochloride; Esophageal Neoplasms; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Neoplasms; Outcome Assessment, Health Care; Panitumumab; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2021 |
Erlotinib for Progressive Brain and Leptomeningeal Metastases From HER2-positive Breast Cancer After Treatment Failure With Trastuzumab and Lapatinib: Experience and Review of Literature.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Breast Neoplasms; Erlotinib Hydrochloride; Female; Humans; Meningeal Neoplasms; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Treatment Outcome | 2018 |
The theoretical foundation and research progress for WBRT combined with erlotinib for the treatment of multiple brain metastases in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Brain Neoplasms; Chemoradiotherapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
Erlotinib: early clinical development in brain cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2014 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
[Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2015 |
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Erlotinib for the treatment of brain metastases in non-small cell lung cancer.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Retrospective Studies | 2016 |
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2016 |
Pulsatile Erlotinib in EGFR-Positive Non-Small-Cell Lung Cancer Patients With Leptomeningeal and Brain Metastases: Review of the Literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Dosage Calculations; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Treatment Outcome | 2017 |
Insights into pharmacotherapy of malignant glioma in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Glioma; Humans; Quinazolines; Temozolomide | 2009 |
Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Drug Combinations; Drug Synergism; Erlotinib Hydrochloride; Glioma; Humans; Models, Biological; Neoplasm Grading; Quinazolines | 2011 |
Erlotinib in glioblastoma: lost in translation?
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2011 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
Role of chemotherapy on brain metastasis.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2005 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2006 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
49 trial(s) available for erlotinib hydrochloride and Brain Neoplasms
| Article | Year |
|---|---|
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Genes, erbB-1; Hong Kong; Humans; Injections, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Placebos; Progression-Free Survival; Ramucirumab; Republic of Korea; Taiwan; Treatment Outcome | 2020 |
Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; China; Cranial Irradiation; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2021 |
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Europe; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Mutation; Placebos; Progression-Free Survival; Ramucirumab; Response Evaluation Criteria in Solid Tumors; Survival Rate; United States; Young Adult | 2021 |
Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases.
Topics: Acrylamides; Aged; Aniline Compounds; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Ramucirumab | 2021 |
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Random Allocation; Survival Analysis; Treatment Outcome | 2021 |
Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Cerebrovascular Circulation; Child; Child, Preschool; Contrast Media; Erlotinib Hydrochloride; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Prognosis; Treatment Failure; Young Adult | 2018 |
Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?
Topics: Adolescent; Antineoplastic Agents; Brain Neoplasms; Child; Disease Progression; Erlotinib Hydrochloride; Glioma; Humans; Magnetic Resonance Imaging; Neuroimaging; Prognosis; Prospective Studies; Radiotherapy Dosage; Regression Analysis; Treatment Failure | 2017 |
Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Radiosurgery; Survival Rate | 2019 |
De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
Topics: Adult; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Lapatinib; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Survival Rate; Tissue Distribution; Young Adult | 2014 |
A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Chemoradiotherapy; Combined Modality Therapy; Dacarbazine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Quinazolines; Temozolomide; Young Adult | 2014 |
Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cranial Irradiation; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recovery of Function; Treatment Outcome | 2014 |
Adding Erlotinib to Chemoradiation Improves Overall Survival but Not Progression-Free Survival in Stage III Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Intensity-Modulated; Time Factors | 2015 |
A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.
Topics: Adult; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Modification Methylases; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Prognosis; Radiotherapy; Temozolomide; Treatment Outcome; Young Adult | 2016 |
Identification of a novel HER3 activating mutation homologous to EGFR-L858R in lung cancer.
Topics: Adolescent; Amino Acid Sequence; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; ErbB Receptors; Erlotinib Hydrochloride; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Neuregulin-1; Phosphorylation; Prospective Studies; Protein Kinase Inhibitors; Protein Structure, Tertiary; Receptor, ErbB-2; Receptor, ErbB-3; Tomography, X-Ray Computed | 2016 |
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2016 |
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carboplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2008 |
Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Neoplasms; Brain Neoplasms; Child; Child, Preschool; Dacarbazine; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Quinazolines; Rhabdomyosarcoma; Temozolomide | 2008 |
Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Glioblastoma; Gliosarcoma; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Temozolomide | 2009 |
Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.
Topics: Adolescent; Adult; Anticonvulsants; Brain Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2009 |
Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carmustine; Dacarbazine; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Temozolomide | 2009 |
Phase I study of concurrent whole brain radiotherapy and erlotinib for multiple brain metastases from non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Cranial Irradiation; Dose Fractionation, Radiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2009 |
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2009 |
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease-Free Survival; DNA Modification Methylases; DNA Repair Enzymes; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Karnofsky Performance Status; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiotherapy; Temozolomide; Tumor Suppressor Proteins; Young Adult | 2010 |
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Young Adult | 2010 |
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Glioma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tissue Distribution | 2010 |
[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Smoking; Survival Rate | 2010 |
Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2010 |
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Survival Rate; Tissue Distribution | 2010 |
Population analysis of erlotinib in adults and children reveals pharmacokinetic characteristics as the main factor explaining tolerance particularities in children.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Squamous Cell; Child; Child, Preschool; Cytochrome P-450 CYP3A; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Young Adult | 2011 |
Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dasatinib; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Pyrimidines; Quinazolines; Thiazoles; Tissue Distribution; Young Adult | 2012 |
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Sequence Deletion; Treatment Outcome | 2012 |
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Sirolimus; Survival Rate; Tissue Distribution | 2012 |
Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma.
Topics: Adult; Aged; Anticonvulsants; Astrocytoma; Brain Neoplasms; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Recurrence | 2012 |
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2013 |
Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Proteins; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Proteomics; Quinazolines; Survival Analysis | 2013 |
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution | 2013 |
Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cranial Irradiation; Drug Administration Schedule; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Treatment Outcome | 2013 |
A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Dacarbazine; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Radiotherapy Dosage; Temozolomide | 2013 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Interactions; Erlotinib Hydrochloride; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Temozolomide; Treatment Outcome | 2006 |
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage | 2006 |
Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
Topics: Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Child; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Quinazolines | 2007 |
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention | 2008 |
114 other study(ies) available for erlotinib hydrochloride and Brain Neoplasms
| Article | Year |
|---|---|
Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Drug Delivery Systems; Glioma; Neoplasm Invasiveness; Rats; Transplantation, Heterologous | 2013 |
CBX3 accelerates the malignant progression of glioblastoma multiforme by stabilizing EGFR expression.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromosomal Proteins, Non-Histone; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Ubiquitin-Protein Ligases; Ubiquitination | 2022 |
The "SEED" Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors.
Topics: Brain Neoplasms; Child; Dasatinib; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Humans; Neoplasm Recurrence, Local; Patient Selection; Prospective Studies; Sorafenib; Young Adult | 2022 |
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non-Small Cell Lung Cancer.
Topics: Afatinib; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Retrospective Studies | 2023 |
Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC.
Topics: Afatinib; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Treatment Outcome | 2023 |
Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Metastasis; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies; Taiwan | 2019 |
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Topics: Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Treatment Outcome | 2019 |
Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Retrospective Studies; Sequence Deletion | 2019 |
Cooperative Blockade of PKCα and JAK2 Drives Apoptosis in Glioblastoma.
Topics: Acrylamides; Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Indoles; Janus Kinase 2; Mice; Morpholines; Protein Kinase C-alpha; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Young Adult | 2020 |
Epidermal Growth Factor (EGF) Augments the Invasive Potential of Human Glioblastoma Multiforme Cells via the Activation of Collaborative EGFR/ROS-Dependent Signaling.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitochondria; Reactive Oxygen Species; Signal Transduction | 2020 |
Safety and CSF distribution of high-dose erlotinib and gefitinib in patients of non-small cell lung cancer (NSCLC) with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Tandem Mass Spectrometry | 2020 |
Tailored therapy for recurrent glioblastoma: report of a personalized molecular approach.
Topics: Bevacizumab; Brain Neoplasms; Erlotinib Hydrochloride; Glioblastoma; Humans; Neoplasm Recurrence, Local; Vascular Endothelial Growth Factor A | 2023 |
Survival analysis of afatinib versus erlotinib for individuals with advanced del19 lung adenocarcinoma with asymptomatic brain metastasis after pemetrexed-cisplatin chemotherapy: a retrospective study.
Topics: Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Survival Analysis | 2020 |
Therapy-Induced Transdifferentiation Promotes Glioma Growth Independent of EGFR Signaling.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transdifferentiation; Datasets as Topic; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Regulation, Neoplastic; Glioma; Homeodomain Proteins; Humans; Male; Mice; Mice, Knockout; Neoplasm Recurrence, Local; Prognosis; Progression-Free Survival; RNA-Seq; Signal Transduction; Transcription Factors; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2021 |
The past, present, and future management of brain metastases in EGFR-mutant non-small cell lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms | 2021 |
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines | 2017 |
Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Survival Analysis; Treatment Failure; Treatment Outcome | 2017 |
Extracellular Hyaluronic Acid Influences the Efficacy of EGFR Tyrosine Kinase Inhibitors in a Biomaterial Model of Glioblastoma.
Topics: Acrylamides; Animals; Biocompatible Materials; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gelatin; Glioblastoma; Humans; Hyaluronic Acid; Hydrogels; Matrix Metalloproteinase 2; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Up-Regulation | 2017 |
Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Brain Neoplasms; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Treatment Outcome; Tumor Burden | 2018 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Erlotinib Hydrochloride; Glioblastoma; Humans; Piperazines; Pyridines; Retinoblastoma Protein; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2018 |
Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Calgranulin B; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Myeloid-Derived Suppressor Cells; Prognosis; Survival Rate | 2018 |
Design of a Multicompartment Hydrogel that Facilitates Time-Resolved Delivery of Combination Therapy and Synergized Killing of Glioblastoma.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Erlotinib Hydrochloride; Glioblastoma; Humans; Hydrogels; Peptides; Protein Kinase Inhibitors | 2018 |
Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line, Tumor; Cell-Penetrating Peptides; Chitosan; Doxorubicin; Drug Delivery Systems; Endothelial Cells; Erlotinib Hydrochloride; Glioblastoma; Humans; Liposomes; Models, Biological; Neuroglia; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Binding; Receptors, Transferrin; Tissue Scaffolds; Transferrin | 2019 |
Eight-year survival of a recurrent glioblastoma patient treated with molecularly tailored therapy: a case report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Erlotinib Hydrochloride; Glioblastoma; Humans; Male; Neoplasm Recurrence, Local; Precision Medicine; Progression-Free Survival | 2018 |
Efficacy of nano-particulated, water-soluble erlotinib against intracranial metastases of EGFR-mutant lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mice, SCID; Mutation; Nanoparticles; Water | 2018 |
Erlotinib versus gefitinib for brain metastases in Asian patients with exon 19 EGFR-mutant lung adenocarcinoma: a retrospective, multicenter study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Asian People; Brain Neoplasms; China; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Retrospective Studies; Survival Analysis | 2018 |
Monitoring Treatment Response to Erlotinib in EGFR-mutated Non-small-cell Lung Cancer Brain Metastases Using Serial O-(2-[
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Positron-Emission Tomography; Tyrosine | 2019 |
Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Treatment Outcome | 2019 |
Erlotinib-Associated Rash Exacerbated by Whole-Brain Radiation Therapy: A Patient's Case Report.
Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Brain Neoplasms; Chemoradiotherapy; Cranial Irradiation; Disease Progression; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Face; Female; Humans; Lung Neoplasms; Radiodermatitis; Skin; Treatment Outcome | 2019 |
Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Cranial Irradiation; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Radiosurgery; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2019 |
The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells.
Topics: Brain Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Forkhead Box Protein O3; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; Transcriptional Activation; Trifluoperazine | 2019 |
Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Doxorubicin; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Liposomes; Male; Mice, Nude; Nanoparticles; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution; Transferrin | 2019 |
Hyaluronic acid-functionalized gelatin hydrogels reveal extracellular matrix signals temper the efficacy of erlotinib against patient-derived glioblastoma specimens.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gelatin; Glioblastoma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydrogels; Mice; Neoplasm Invasiveness; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; STAT3 Transcription Factor; Treatment Outcome; Tumor Microenvironment; Up-Regulation | 2019 |
[A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.
Topics: Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Forkhead Transcription Factors; Gene Amplification; Glioblastoma; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2013 |
Molecular imaging of drug transit through the blood-brain barrier with MALDI mass spectrometry imaging.
Topics: Animals; Antineoplastic Agents; Biomarkers; Blood-Brain Barrier; Brain Neoplasms; Disease Models, Animal; Erlotinib Hydrochloride; Glioma; Heme; Heterografts; Humans; Mice; Molecular Imaging; Neovascularization, Pathologic; Optical Imaging; Permeability; Pharmaceutical Preparations; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2013 |
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Failure | 2014 |
Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Brain Neoplasms; Cranial Irradiation; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2014 |
Prognostic factors for brain metastases from non-small cell lung cancer with EGFR mutation: influence of stable extracranial disease and erlotinib therapy.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Expression; Glioblastoma; Humans; Lapatinib; Mice; Quinazolines; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain; Brain Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dacarbazine; Erlotinib Hydrochloride; Follow-Up Studies; Glioblastoma; Humans; Image Processing, Computer-Assisted; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Outcome Assessment, Health Care; Prognosis; Quinazolines; Temozolomide; Young Adult | 2015 |
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Membrane Proteins; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction | 2015 |
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured | 2015 |
Radiation-Refractory Brain Metastases in Patients with Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2015 |
Afatinib-refractory brain metastases from EGFR-mutant non-small-cell lung cancer successfully controlled with erlotinib: a case report.
Topics: Afatinib; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
An unusual response with long term survival using erlotinib in NSCLC lung with brain metastases.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Survival Rate | 2016 |
Supramolecular Probes for Assessing Glutamine Uptake Enable Semi-Quantitative Metabolic Models in Single Cells.
Topics: Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence Resonance Energy Transfer; Glioblastoma; Glutamine; Humans; Molecular Probes | 2016 |
A Thermodynamic-Based Interpretation of Protein Expression Heterogeneity in Different Glioblastoma Multiforme Tumors Identifies Tumor-Specific Unbalanced Processes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Computational Biology; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genetic Heterogeneity; Glioblastoma; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasm Proteins; Phosphoproteins; Signal Transduction; Thermodynamics | 2016 |
Metastatic Adenoid Cystic Carcinoma Mimicking Butterfly Glioblastoma: A Rare Presentation in the Splenium of the Corpus Callosum.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Adenoid Cystic; Chemotherapy, Adjuvant; Corpus Callosum; Cranial Irradiation; Decompression, Surgical; Diagnosis, Differential; Erlotinib Hydrochloride; Glioblastoma; Humans; Kidney Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Metastasectomy; Parotid Neoplasms; Radiotherapy, Adjuvant | 2016 |
Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Genomics; Glioma; Humans; Male; Middle Aged; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2016 |
Management Difficulties in a Patient with EGFR-mutation Positive Lung Adenocarcinoma and Cerebral Metastases.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Remission Induction; Salvage Therapy; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2017 |
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Drug interaction between erlotinib and phenytoin for brain metastases in a patient with nonsmall cell lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP3A; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Seizures; Treatment Outcome | 2016 |
Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Radiosurgery; Retrospective Studies; Salvage Therapy; Survival Rate | 2017 |
Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Treatment Failure | 2017 |
Erlotinib therapy in a patient with non-small-cell lung cancer and brain metastases.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines | 2008 |
Trichomegaly of the eyelashes after lung cancer treatment with the epidermal growth factor receptor inhibitor erlotinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Brain Neoplasms; Carcinoma, Bronchogenic; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Follow-Up Studies; Humans; Hypertrichosis; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Quinazolines; Risk Assessment | 2008 |
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking | 2009 |
New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Erlotinib Hydrochloride; Gefitinib; Humans; Infant; Quinazolines; Treatment Outcome; Young Adult | 2009 |
Epidermal growth factor receptor exon 19 deletions predict complete regression of multiple intracranial metastases in two cases of non-small cell lung cancer treated with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Exons; Fatal Outcome; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2009 |
Pharmacokinetics of erlotinib for the treatment of high-grade glioma in a pediatric patient with cystic fibrosis: case report and review of the literature.
Topics: Biological Availability; Brain Neoplasms; Child; Combined Modality Therapy; Cystic Fibrosis; Erlotinib Hydrochloride; Exocrine Pancreatic Insufficiency; Female; Glioma; Humans; Malabsorption Syndromes; Pancrelipase; Protein Kinase Inhibitors; Quinazolines | 2009 |
EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Brain Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Hepatocyte Growth Factor; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Knockout; Mice, Nude; Mice, SCID; Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
[A case of non-small cell lung cancer treated safely by whole brain radiation therapy and erlotinib].
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
[Erlotinib and nonsmall cell lung cancer with brain metastases: a case study with a complete and prolonged response over 17 months].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2009 |
New-onset acute interstitial lung disease after treatment with erlotinib in a patient with metastatic squamous cell carcinoma of the lung.
Topics: Aged; Biopsy; Brain Neoplasms; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pneumonia; Quinazolines; Tomography, X-Ray Computed | 2011 |
[Lung cancer: an update in 2010].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Interstitial infusion of erlotinib in the rodent brain.
Topics: Animals; Body Weight; Brain; Brain Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Microinjections; Neostriatum; Quinazolines; Rats; Rats, Nude | 2009 |
Clinical outcomes in extracranial tumor sites and unusual toxicities with concurrent whole brain radiation (WBRT) and Erlotinib treatment in patients with non-small cell lung cancer (NSCLC) with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; Drug Interactions; Erlotinib Hydrochloride; Female; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome; Whole-Body Irradiation | 2010 |
A new prognostic score derived from phase I study participants with advanced solid tumours is also valid in patients with brain metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Brain Neoplasms; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Databases, Factual; Erlotinib Hydrochloride; Humans; Indoles; Middle Aged; Neoplasms; Prognosis; Pyrroles; Quinazolines; Severity of Illness Index; Sunitinib; Trastuzumab | 2010 |
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN.
Topics: Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Glioblastoma; Goiter, Nodular; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; PTEN Phosphohydrolase; Quinazolines; Radiotherapy | 2010 |
Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Folliculitis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paronychia; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2010 |
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.
Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
Recovery from carcinomatous meningitis by erlotinib.
Topics: Adenocarcinoma; Aged; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Synergistic induction of apoptosis in brain cancer cells by targeted codelivery of siRNA and anticancer drugs.
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Carriers; Drug Compounding; ErbB Receptors; Erlotinib Hydrochloride; Gene Silencing; Glioblastoma; Humans; Hydroxamic Acids; Ligands; Neoplasm Proteins; Particle Size; PC12 Cells; Quinazolines; Rats; RNA, Small Interfering; Vorinostat | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mutation; Quinazolines; Radionuclide Imaging | 2011 |
Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2011 |
Case records of the Massachusetts General Hospital. Case 31-2011. A 55-year-old man with oligometastatic lung cancer.
Topics: Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Radiography | 2011 |
Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Brain Neoplasms; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gene Deletion; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, SCID; Mutation; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Glioma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tumor Cells, Cultured; Young Adult | 2012 |
The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Erlotinib in symptomatic brain metastases from a lung adenocarcinoma with a sensitizing EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Biopsy; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Occupy EGFR.
Topics: Animals; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Kinetics; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Glioma; Humans; Lapatinib; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.
Topics: Animals; Astrocytes; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Mutant Strains; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tyrosine | 2012 |
Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Factors; Survival Rate | 2012 |
Erlotinib-induced bullous pemphigoid.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Pemphigoid, Bullous; Quinazolines | 2012 |
Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Fluorescent Antibody Technique; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Neoplastic Stem Cells; Quinazolines; Veratrum Alkaloids | 2012 |
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Complete response to erlotinib treatment in brain metastases from recurrent NSCLC.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2006 |
Evolution of management strategies for cerebral gliomas: the effects of science and technology.
Topics: Antibiotics, Antineoplastic; Brain Neoplasms; DNA Repair; DNA-Binding Proteins; Doxorubicin; Endonucleases; Erlotinib Hydrochloride; Gene Silencing; Genes, erbB-1; Genome, Human; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Xeroderma Pigmentosum Group D Protein | 2005 |
Erlotinib induced skin rash spares skin in previous radiotherapy field.
Topics: Adenocarcinoma; Back; Brain Neoplasms; Chemotherapy, Adjuvant; Drug Eruptions; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Reoperation; Skin; Thoracic Wall | 2006 |
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
Recurrent responses to non-small cell lung cancer brain metastases with erlotinib.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Survival Rate; Xenograft Model Antitumor Assays | 2007 |
Significant drug interaction: phenytoin toxicity due to erlotinib.
Topics: Anticonvulsants; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Erlotinib Hydrochloride; Fatal Outcome; Female; Humans; Lung Neoplasms; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Quinazolines; Seizures | 2007 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Exacerbated radiodermatitis and bilateral subdural hemorrhage after whole brain irradiation combined with epidermal growth factor receptor tyrosine kinase inhibitors for brain metastases in lung cancer.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Fatal Outcome; Hematoma, Subdural; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2008 |
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Indoles; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Signal Transduction; Sulfonamides | 2007 |
CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2007 |
Response of intracranial metastases to erlotinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2007 |
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2008 |
Erlotinib in patients with previously irradiated, recurrent brain metastases from non-small cell lung cancer: two case reports.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2008 |